All In Biotech

Drug Trial Radar · NCT00148941

Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines

Safety, Immunogenicity and Consistency of 3 Manufacturing Lots of DTaP-IPV Vaccine Versus Separate Injections of GSK Biologicals' DTaP + Aventis Pasteur's IPV Administered as Booster Doses to Healthy Children 4-6 Years, Each Co-administered With Merck's MMR Vaccine

Last checked: Nov 20, 2026Latest source record: Feb 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,209 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,209

Actual

Start

Jan 6, 2005

Primary completion

Nov 1, 2006

Study completion Dec 4, 2006

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Sep 8, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 4 years, up to 6 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aims of this trial are to demonstrate the consistency of three manufacturing lots of GSK Biologicals' DTaP-IPV candidate vaccine in terms of immunogenicity and to evaluate the non-inferiority of GSK Biologicals' DTaP-IPV vaccine with respect to immunogenicity and safety compared to the control vaccines (separate injections of GSK Biologicals' DTaP vaccine \[Infanrix\] and Aventis Pasteur's IPV vaccine \[IPOL\]) when administered as a 5th dose of DTaP and a 4th dose of inactivated poliovirus vaccine in subjects 4 to 6 years of age. Vaccines will be co-administered with the second dose of M-M-RII, which is recommended at this age. Concomitant administration of a US-licensed influenza vaccine will be allowed according to seasonal availability of vaccine and at the discretion of the investigator.

Conditions

  • Tetanus
  • Acellular Pertussis
  • Diphtheria

Interventions

  • SB213503 lot 1Biological

    SB213503 lot 1 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.

  • SB213503 lot 2Biological

    SB213503 lot 2 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.

  • SB213503 lot 3Biological

    SB213503 lot 3 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.

  • InfanrixBiological

    Infanrix vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.

  • IPOLBiological

    IPOL vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.

  • M-M-R IIBiological

    M-M-R II vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean Concentrations (GMCs) for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies in a Subset of SubjectsTime frame: At Month 1 (i.e. one month after vaccination)
  2. Geometric Mean Concentrations (GMCs) for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies in a Subset of SubjectsTime frame: At Month 1 (i.e. one month after vaccination)
  3. Geometric Mean Titers (GMTs) for Anti-poliovirus Types 1, 2 and 3 Antibodies in a Subset of SubjectsTime frame: At Month 1 (i.e. one month after vaccination)
  4. Number of Subjects With Booster Response Against Diphtheria Toxoid (D) and Tetanus Toxoid (T) Antigens in a Subset of SubjectsTime frame: At Month 1 (i.e. one month after vaccination)
  5. Number of Subjects With Booster Response Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) Antigens in a Subset of SubjectsTime frame: At Month 1 (i.e. one month after vaccination)
  6. Number of Subjects With Circumferential Swelling at the Injection SiteTime frame: Within 4 days (Day 0-3) after vaccination

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Antioch, California

  • GSK Investigational Site

    Daly City, California

  • GSK Investigational Site

    Fairfield, California

  • GSK Investigational Site

    Fremont, California

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Hayward, California

  • GSK Investigational Site

    Oakland, California

  • GSK Investigational Site

    Pleasanton, California

  • GSK Investigational Site

    Redwood City, California

  • GSK Investigational Site

    Richmond, California

  • GSK Investigational Site

    Roseville, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    San Jose, California

  • GSK Investigational Site

    San Ramon, California

  • GSK Investigational Site

    Santa Clara, California

  • GSK Investigational Site

    Santa Rosa, California

  • GSK Investigational Site

    Vacaville, California

  • GSK Investigational Site

    Vallejo, California

  • GSK Investigational Site

    Walnut Creek, California

  • GSK Investigational Site

    Columbus, Ohio

  • GSK Investigational Site

    Mechanicsville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.